# Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

> **NCT00784524** · PHASE2 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 14 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** allogeneic large multivalent immunogen breast cancer vaccine
- **BIOLOGICAL:** aldesleukin

## Key facts

- **NCT ID:** NCT00784524
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-09
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Slow accrual
- **Last updated:** 2019-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00784524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00784524, "Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca". Retrieved via AI Analytics 2026-08-01 from https://api.ai-analytics.org/clinical/NCT00784524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*